Abstract
Targeted, mechanism-based therapies are needed for patients with FSGS and MCD, as diverse biological processes produce similar histologic injury patterns. Bulk transcriptomic data from kidney biopsy tissue can be used to find subgroups with shared molecular features, and cellular sources of signaling can be identified in single cell (sc-) and single nuclear (sn-)RNAseq profiles.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
